194 related articles for article (PubMed ID: 28148945)
21. FDA plans to continue cracking down on unapproved drugs.
Lavine G
Am J Health Syst Pharm; 2008 Sep; 65(17):1594. PubMed ID: 18714097
[No Abstract] [Full Text] [Related]
22. Oncology's first Phase 0 trial.
Rowan K
J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
[No Abstract] [Full Text] [Related]
23. Market watch: Value of 2016 FDA drug approvals: reversion to the mean?
Schulze U; Ringel M; Panier V; Baedeker M
Nat Rev Drug Discov; 2017 Feb; 16(2):78. PubMed ID: 28148943
[No Abstract] [Full Text] [Related]
24. Investigational drug tracking: phases I-III and NDA submissions--Part II.
Grant KL
Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
[TBL] [Abstract][Full Text] [Related]
25. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
26. FDA allows second experimental drug to be tested in Ebola patients.
McCarthy M
BMJ; 2014 Aug; 349():g5103. PubMed ID: 25113141
[No Abstract] [Full Text] [Related]
27. FDA approves Aptivus (tipranavir).
Pham PA
Hopkins HIV Rep; 2005 Jul; 17(4):6-7. PubMed ID: 16419308
[No Abstract] [Full Text] [Related]
28. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
29. Market watch: Upcoming market catalysts in Q3 2016.
Ranj T
Nat Rev Drug Discov; 2016 Jul; 15(7):449. PubMed ID: 27282354
[No Abstract] [Full Text] [Related]
30. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
Moss RW
New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
[No Abstract] [Full Text] [Related]
31. Investigational drug access taken to task in lawsuit against FDA.
Randal J
J Natl Cancer Inst; 2003 Dec; 95(24):1818-20. PubMed ID: 14679146
[No Abstract] [Full Text] [Related]
32. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
Roberts SA; Allen JD; Sigal EV
Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
[TBL] [Abstract][Full Text] [Related]
33. Expanded clinical trials of treatments for multiple sclerosis: copolymer 1 (COP-1) treatment investigational new drug (IND) program.
Stark Y
Ann Neurol; 1994 Jul; 36(1):114-5. PubMed ID: 8024251
[No Abstract] [Full Text] [Related]
34. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.
Bateman-House A; Robertson CT
JAMA Intern Med; 2018 Mar; 178(3):321-322. PubMed ID: 29356821
[No Abstract] [Full Text] [Related]
35. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
Prowell T
Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
[No Abstract] [Full Text] [Related]
36. FDA approves aflibercept (Zaltrap) for metastatic colorectal cancer.
Oncology (Williston Park); 2012 Sep; 26(9):842, 873. PubMed ID: 23061342
[No Abstract] [Full Text] [Related]
37. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
38. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
Khozin S; Liu K; Jarow JP; Pazdur R
Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
[No Abstract] [Full Text] [Related]
39. 124 drugs currently in development.
AIDS Patient Care STDS; 1998 Feb; 12(2):149. PubMed ID: 11361916
[No Abstract] [Full Text] [Related]
40. Controversy trails adaptive clinical trials.
Goozner M
J Natl Cancer Inst; 2012 Sep; 104(18):1347-8. PubMed ID: 22984199
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
